Google NewsSandfire Resources Shares Hit New ATH Today, Up 27% on Month: The Latest - thebull.com.au
Sandfire Resources Shares Hit New ATH Today, Up 27% on Month: The Latest thebull.com.au
Alterity Therapeutics (ATH) News
Latest articles and price-sensitive announcements with AI sentiment classification.
StockheadLong Shortz with Alterity Therapeutics: New US patent extends ATH434’s commercial runway
A new US patent strengthens ATH434's long-term commercial potential as Alterity prepares for a Phase 3 trial. ... Read More The post Long Shortz with Alterity Therapeutics: New US patent extends ATH434’s commercial runway appeared first on Stockhead.
Fisher & Paykel Healthcare Shares Hit New ATH. What Now? - thebull.com.au
Fisher & Paykel Healthcare Shares Hit New ATH. What Now? thebull.com.au
ASXAlterity Therapeutics Limited (ASX:ATH) Share Price Falls 4.46% as Stock Trades Within Daily Range - Kalkine
Alterity Therapeutics Limited (ASX:ATH) Share Price Falls 4.46% as Stock Trades Within Daily Range Kalkine
Alterity strengthens IP with new US patent for ATH434 ahead of Phase III MSA trial
Titled “Crystalline Form, and Process for its Production”, the patent was granted by the USPTO. ... Read More The post Alterity strengthens IP with new US patent for ATH434 ahead of Phase III MSA trial appeared first on Stockhead.
KalkineWhy Is Alterity Therapeutics (ASX:ATH) Back in Focus Among ASX Healthcare Stocks?
Highlights Alterity Therapeutics is in focus after a fresh company disclosure added new context to the public record. The healthcare stocks lens centres on clinical progress, regulatory pathways, commercial execution and funding discipline. The broader Australian market backdrop remains important when reading company-specific developments. Australian shares are being assessed against a shifting mix of company updates, sector conditions and global market signals, making fresh disclosures espec...
Small CapsGranted New U.S. Composition of Matter Patent for ATH434
other announcement
Sunrise Energy Metals Shares Hit New ATH To Lead ASX 200: What Is Driving The Move? - thebull.com.au
Sunrise Energy Metals Shares Hit New ATH To Lead ASX 200: What Is Driving The Move? thebull.com.au
Alterity Therapeutics Ltd (ASX: ATH) Share Price Update: Stock Movement and Biotechnology Sector Trends on August 7, 2026 - Kalkine
Alterity Therapeutics Ltd (ASX: ATH) Share Price Update: Stock Movement and Biotechnology Sector Trends on August 7, 2026 Kalkine
Alterity to Present at Canaccord Genuity Growth Conference
other announcement
Alterity Therapeutics (ASX:ATH) Gains Ground as FDA Clears Pathway Toward ATH434 Phase 3 Trial - Kalkine
Alterity Therapeutics (ASX:ATH) Gains Ground as FDA Clears Pathway Toward ATH434 Phase 3 Trial Kalkine
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
Alterity to Participate in the BTIG Biotechnology Conference
other announcement
Alterity Therapeutics (ASX: ATH) Gains as Market Focus Turns to Neurodegenerative Disease Pipeline - Kalkine
Alterity Therapeutics (ASX: ATH) Gains as Market Focus Turns to Neurodegenerative Disease Pipeline Kalkine
Biocurious: Alterity “off to the races” in quest for Multiple System Atrophy cure
The developer of a drug for the rare multiple system atrophy, Alterity is poised to launch a pivotal phase III ... Read More The post Biocurious: Alterity “off to the races” in quest for Multiple System Atrophy cure appeared first on Stockhead.
Alterity Therapeutics (ASX:ATH) Falls as Biotech Volatility Returns to the ASX - Kalkine
Alterity Therapeutics (ASX:ATH) Falls as Biotech Volatility Returns to the ASX Kalkine
StockTake: Alterity receives $4m R&D tax boost ahead of pivotal Phase III MSA trial
Alterity Therapeutics receives nearly $4m in R&D tax funding ahead of its pivotal Phase 3 MSA trial. ... Read More The post StockTake: Alterity receives $4m R&D tax boost ahead of pivotal Phase III MSA trial appeared first on Stockhead.
Alterity kicks FDA goal as US regulator backs Phase III pathway for ATH434 in MSA
Alterity is on track to start Phase III trial activities by the end of 2026. ... Read More The post Alterity kicks FDA goal as US regulator backs Phase III pathway for ATH434 in MSA appeared first on Stockhead.
FDA Meeting Minutes Confirm Registrational Path for ATH434
other announcement
Health Kick Podcast: Alterity gears up for pivotal Phase 3 study
Following positive Phase 2 results, Alterity has aligned with the US FDA on the design of its pivotal Phase 3 ... Read More The post Health Kick Podcast: Alterity gears up for pivotal Phase 3 study appeared first on Stockhead.
ASX: ATH — Alterity Therapeutics Wins Key FDA Alignment as Neuro Trial Hopes Rise - Kalkine
ASX: ATH — Alterity Therapeutics Wins Key FDA Alignment as Neuro Trial Hopes Rise Kalkine
Change of Director's Interest Notice x 2
director_dealing announcement
Notification regarding unquoted securities - ATH
other announcement
Alterity Therapeutics (ASX:ATH) Stock in Focus After FDA Endorses Registrational Pathway for ATH434 - Kalkine
Alterity Therapeutics (ASX:ATH) Stock in Focus After FDA Endorses Registrational Pathway for ATH434 Kalkine
Alterity and FDA Agree on Phase 3 Program for ATH434 in MSA
other announcement
Alterity Reshapes Capital Structure as Phase 3 Ambitions Take Centre Stage
Highlights Alterity Therapeutics has commenced a share consolidation and introduced a temporary ASX ticker during the transition period. The move is designed to simplify the company's capital structure as it advances its lead neurodegenerative disease program. Market attention is increasingly focused on the company's preparations for a pivotal late-stage clinical trial. Alterity Therapeutics has streamlined its capital structure as it continues advancing its lead neurodegenerative disease pro...
Share Consolidation Effective, Trading Under ATHDA
other announcement
Alterity Therapeutics (ASX:ATH) Moves Toward Phase III Planning as MSA Research Gains Attention - Kalkine
Alterity Therapeutics (ASX:ATH) Moves Toward Phase III Planning as MSA Research Gains Attention Kalkine
Alterity in spotlight at medical conferences as MSA clinical research moves toward Phase III planning
Presentations at key medical conferences in May support advancement of Alterity’s lead drug ATH434 into Phase III development for Multiple ... Read More The post Alterity in spotlight at medical conferences as MSA clinical research moves toward Phase III planning appeared first on Stockhead.
Alterity Data Supports ATH434 Phase 3 Advancement in MSA
other announcement
Alterity strengthens ATH434 case with validated brain imaging biomarker in MSA
Alterity bioMUSE study shows advanced MRI imaging detects iron changes in the brain linked to diagnosis and severity in patients ... Read More The post Alterity strengthens ATH434 case with validated brain imaging biomarker in MSA appeared first on Stockhead.
Alterity Announces Publication on MRI as Biomarker for MSA
other announcement
Alterity to Deliver Presentations at May Medical Meetings
other announcement
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
Alterity Receives Positive FDA Feedback on CMC Meeting
other announcement
Alterity Presents New Analysis of ATH434 Phase 2 Data at AAN
other announcement
Notification regarding unquoted securities - ATH
other announcement